EFPIA welcomes Commission policy strategy agenda to strengthen Pharma competitiveness
The European Federation of Pharmaceutical Industries and Associations (EFPIA) welcomes the European Commission Communication on industrial policy as an important step to seeking to secure the competitiveness of the European Union pharmaceutical industry and protect access to medicines for all of Europe’s citizens.
Sir Andrew Witty, the EFPIA president and chief executive of GlaxoSmithKline, said: “Innovation is vital to any successful long-term economic strategy. Pharmaceutical innovation can be one of the key platforms of a growth programme for Europe. The pharmaceuticals sector is by far EU’s most R&D intensive industry. Europe is a world leader in this area, but other locations, such as the USA and certain Asian countries, present increasingly strong competition for manufacturing and R&D activities.”
Lack of coordination on pricing and reimbursement recognized
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze